Alexion Pharm Inc (ALXN)
Ex-Pharma Executive Avoids Prison for Tipping Pal About Merger
A former Alexion Pharmaceuticals Inc. executive avoided jail after pleading guilty to sharing information about the company’s planned purchase of another company in 2020 with a boyhood friend.
Wilson Disease Drugs Market Analysis Growth Challenges, Opportunities and Future Developments to 2029
Will Moderna’s Tenure on the S&P 500 Index Be Short-Lived?
It's not likely.
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna Stock Leapt 4.5% After Joining S&P 500. Why Analysts Don't Expect More Gains.
With shares at record-high prices now, very few on Wall Street still see upside in the stock.
ALXN vs. TECH: Which Stock Is the Better Value Option?
ALXN vs. TECH: Which Stock Is the Better Value Option?
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS
The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag
The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.
Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance
Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock has soared amid the pandemic after its vaccine became instrumental in the fight against coronavirus.
Moderna Soars on Inclusion to S&P 500: ETFs in Focus
Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.
AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?
Probably so.
With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?
With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.
Moderna Stock — Soon To Join S&P 500 — Rockets To Yet Another Record
Moderna stock rocketed to another record high Friday on news it would join the S&P 500 on Wednesday, replacing soon-to-be-acquired Alexion.
Why Moderna Stock Just Jumped 10%
The company joins the S&P 500 index next week.
MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500
Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN).
Stocks Are Higher After Retail Sales Top Expectations
Stock futures were moving higher, while Asian and European equities were mixed as Covid-19 concerns remained in focus.
Global Stocks Mixed Ahead of U.S. Retail Sales Data
Stock futures were moving higher, while Asian and European equities were mixed as Covid-19 concerns remained in focus.
Moderna Set to Join S&P 500
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021
Here is Why Growth Investors Should Buy Alexion (ALXN) Now
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
Vaccine Maker AstraZeneca’s Strong Drug Pipeline Could Lift the Stock Higher for Years
AstraZeneca has a Covid vaccine, but the company is also a specialist in cancer treatments, and it supplies medicine for a host of other diseases.
AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition
AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.
ALXN or GMAB: Which Is the Better Value Stock Right Now?
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Translate Bio Stock Sees Relative Strength Rating Jump To 88
A Relative Strength Rating upgrade for Translate Bio shows improving technical performance.
GlaxoSmithKline Taps Goldman and Citi for Consumer Spinoff
GlaxoSmithKline Plc has hired two banks to help advise on plans to list its consumer unit next year and defend against a potential activist campaign from Elliott Investment Management, according to people familiar with the matter.